2020
DOI: 10.1126/science.abc7424
|View full text |Cite
|
Sign up to set email alerts
|

Broad neutralization of SARS-related viruses by human monoclonal antibodies

Abstract: Broadly protective vaccines against known and pre-emergent human coronaviruses (HCoVs) are urgently needed. To gain a deeper understanding of cross-neutralizing antibody responses, we mined the memory B cell repertoire of a convalescent SARS donor and identified 200 SARS-CoV-2 binding antibodies that target multiple conserved sites on the spike (S) protein. A large proportion of the non-neutralizing antibodies display high levels of somatic hypermutation and cross-react with circulating HCoVs, suggesting recal… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

35
637
3
6

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
5

Relationship

1
9

Authors

Journals

citations
Cited by 589 publications
(692 citation statements)
references
References 28 publications
35
637
3
6
Order By: Relevance
“…Several studies have identified and characterized neutralizing antibodies against SARS-CoV-2 as a potential component of protective immunity 14,[16][17][18][19][20][21][22] . However, to date, only very few studies have focused on evaluating the efficacy of antibodies to protect or prevent against SARS-CoV-2 infection or disease in vivo.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have identified and characterized neutralizing antibodies against SARS-CoV-2 as a potential component of protective immunity 14,[16][17][18][19][20][21][22] . However, to date, only very few studies have focused on evaluating the efficacy of antibodies to protect or prevent against SARS-CoV-2 infection or disease in vivo.…”
Section: Discussionmentioning
confidence: 99%
“…In the post-fusion stage, S1 dissociates from the trimer, while S2 undergoes a dramatic conformational change to trigger host membrane fusion (6). Most recently, investigations into COVID-19 convalescence individuals' sera have led to the identifications of highly potent neutralizing IgG antibodies (NAbs) primarily targeting the RBD but also non-RBD epitopes (7)(8)(9)(10)(11)(12)(13). Highquality NAbs may overcome the risks of the Fc-associated antibody-dependent enhancement (ADE) and are promising therapeutic and prophylactic candidates (14,15).…”
Section: Introductionmentioning
confidence: 99%
“…The major antigen of coronavirus is the spike (S) glycoprotein, which is expressed as a homotrimer on the virus surface. Since the S protein is essential for virus entry through engaging the host receptor and mediating virus-host membrane fusion, many antibodies to the S protein are neutralizing [1][2][3][4][5][6][7][8][9][10][11][12]. The S proteins of SARS-CoV-2 and SARS-CoV, which caused a global outbreak in 2003, have an amino-acid sequence identity of around 77% [13] that leads to differences in antigenicity in serology studies [14,15].…”
Section: Introductionmentioning
confidence: 99%